These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9201199)

  • 21. Advanced non-small cell lung carcinoma: the emerging role of docetaxel.
    Langer CJ
    Invest New Drugs; 2000 Feb; 18(1):17-28. PubMed ID: 10830138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
    Georgoulias V; Kourousis C; Androulakis N; Kakolyris S; Dimopoulos MA; Bouros D; Papadimitriou C; Hatzakis K; Heras P; Kalbakis K; Kotsakis T; Vardakis N; Meramveliotakis N; Hatzidaki D
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-22-S14-25. PubMed ID: 9335520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
    Mavroudis D
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
    [No Abstract]   [Full Text] [Related]  

  • 24. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
    Simon GR; Bunn PA
    Cancer Invest; 2003; 21(1):87-104. PubMed ID: 12643013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of advanced disease and new drugs.
    Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
    Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
    [No Abstract]   [Full Text] [Related]  

  • 26. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
    Hainsworth JD; Burris HA; Greco FA
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):21-5. PubMed ID: 11441411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA; Kelly K
    Clin Cancer Res; 1998 May; 4(5):1087-100. PubMed ID: 9607565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
    Morere JF
    Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S37-41. PubMed ID: 11924242
    [No Abstract]   [Full Text] [Related]  

  • 31. Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
    Mattson K
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):33-6. PubMed ID: 11441413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
    Shepherd FA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):3-11. PubMed ID: 10201515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
    Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
    Georgoulias V
    Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy in metastatic non-small-cell lung cancer.
    Sandler A
    Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The current status of docetaxel for advanced non-small cell lung cancer.
    Green MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New wave of chemotherapeutic agents: update in pulmonary oncology].
    Sculier JP
    Rev Mal Respir; 1997 Apr; 14(2):154-6. PubMed ID: 9198842
    [No Abstract]   [Full Text] [Related]  

  • 39. Docetaxel and gemcitabine released for cancer chemotherapy.
    Am J Health Syst Pharm; 1996 Jul; 53(14):1643, 1649. PubMed ID: 8827226
    [No Abstract]   [Full Text] [Related]  

  • 40. [Phase II study].
    Niitani H
    Gan To Kagaku Ryoho; 1995 Apr; 22(5):607-10. PubMed ID: 7717711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.